Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors within the central anxious process, conolidine modulates alternate molecular targets. A Science Advancements review uncovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which